Novartis Pharma AG: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Novartis Pharma AG: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials and is consistent with the established adult psoriasis indication 1 Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 childre...
Source: finanznachrichten.de